Cuộc họp báo cáo kết quả kinh doanh Q2 2026 của Evogene (EVGN): Mức lỗ thu hẹp khi ChemPass AI mở rộng
Lỗ ròng Quý 2/2026 của Evogene thu hẹp 62% xuống còn 1,8 triệu USD khi các hợp tác ChemPass AI đạt mốc 6. Ban lãnh đạo duy trì dự báo mức sử dụng tiền mặt trong khoảng 8,5–9,5 triệu USD.
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.